Post job

Heat Biologics main competitors are Pharmacyclics, Acorda Therapeutics, and PacBio.

Competitor Summary. See how Heat Biologics compares to its main competitors:

  • Merck has the most employees (74,000).
  • Employees at Pharmacyclics earn more than most of the competitors, with an average yearly salary of $97,383.
Work at Heat Biologics?
Share your experience

Heat Biologics vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2008
4.1
Durham, NC2$2.9M30
1995
4.6
Ardsley, NY3$117.6M344
1991
4.9
Sunnyvale, CA1$235.0M607
1995
4.5
Hopkinton, MA1$109.8M200
1992
4.9
Rockville, MD1$131.0M1,000
1981
4.2
Seattle, WA1$27.0M200
2004
4.7
Menlo Park, CA1$154.0M400
1891
4.6
Kenilworth, NJ31$64.2B74,000
-
3.5
Dayton, OH1$1.6M30

Rate how well Heat Biologics differentiates itself from its competitors.

Zippia waving zebra

Heat Biologics salaries vs competitors

Among Heat Biologics competitors, employees at Pharmacyclics earn the most with an average yearly salary of $97,383.

Compare Heat Biologics salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Heat Biologics
$49,589$23.84-
Acorda Therapeutics
$97,279$46.77-
Pharmacyclics
$97,383$46.82-
Caliper Life Sciences
$81,030$38.96-
Human Genome Sciences
$70,157$33.73-
ZymoGenetics
$90,249$43.39-

Compare Heat Biologics job title salaries vs competitors

CompanyHighest salaryHourly salary
Heat Biologics
$35,211$16.93
Merck
$40,936$19.68
ZymoGenetics
$37,760$18.15
Acorda Therapeutics
$37,176$17.87
PacBio
$36,859$17.72
Caliper Life Sciences
$35,778$17.20
Pharmacyclics
$35,733$17.18
Human Genome Sciences
$35,014$16.83
Ardent Technologies
$33,373$16.04

Do you work at Heat Biologics?

Does Heat Biologics effectively differentiate itself from competitors?

Heat Biologics jobs

Heat Biologics demographics vs competitors

Compare gender at Heat Biologics vs competitors

Job titleMaleFemale
Pharmacyclics42%58%
Merck54%46%
Acorda Therapeutics58%42%
PacBio65%35%
Ardent Technologies84%16%
Heat Biologics--
Male
Female
100%
75%
50%
25%
0%
0%
25%
50%
75%
100%

Compare race at Heat Biologics vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
58%17%11%11%3%
9.4
56%16%10%14%4%
9.8
42%20%5%27%5%
9.6
43%20%6%24%7%
9.6
59%12%6%19%3%
6.1

Heat Biologics and similar companies CEOs

CEOBio

Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as Director and Chairman of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year.

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Christian O. Henry
PacBio

Mike McMullen
Ardent Technologies

Heat Biologics competitors FAQs

Search for jobs